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Although the management of cardiovascular disease con-
tains numerous controversies, there are two issues that
cardiologists appear to agree on: the link between serum
cholesterol and coronary atherosclerosis and the efficacy of
the statin drugs in lowering serum cholesterol concentra-
tion. These drugs have been tested in several well designed
clinical trials of secondary prevention (1–3), and each has
shown favorable findings involving a consistent decrease in
serum cholesterol concentration and a concurrent reduction
in coronary events. In fact, the three major secondary
prevention trials (1–3) have resulted in a pattern of approx-
imately 1% decrease in events for each 1% decline in
LDL-cholesterol. As this evidence accumulates, emphasis
has shifted from “Can we reduce serum cholesterol concen-
tration?” to “How low should we go?” This comment is
written to open a dialogue on this issue with reference to the
management of patients with known coronary artery dis-
ease.
Cardiologists recognize two aspects of preventive cardi-
ology: one dealing with primary risk in individuals having
no previous evidence of coronary disease and the other
concerning secondary risk in patients with clinical evidence
of disease (4,5). In 1990, Pekkanen and his colleagues (6)
addressed this issue using the data base of the Lipid
Research Clinics Program Prevalence Study (LRCPPS),
and identified the relationships between serum cholesterol
concentration and the death rate from coronary artery
disease (per 1,000 individuals/year). They identified two
distinct relationships between coronary mortality and serum
cholesterol level in individuals with no history of coronary
artery disease and in patients with documented coronary
disease (Fig. 1). As illustrated, mortality is closely related to
serum cholesterol concentration, and the correlation is
stronger in patients with, than in patients without, coronary
disease. These relationships form the raison d’etre for
attempting to “treat” elevations in serum cholesterol. The
implication in these two relationships is that a reduction in
serum cholesterol will diminish the risk of death from
coronary artery disease. The observations from the placebo
arms of several large trials (7–9) and observational studies
(10) relating to coronary atherosclerosis have since con-
firmed this disparate relationship between serum cholesterol
and mortality in symptomatic compared with asymptomatic
individuals (Fig. 1). It is of interest to consider the findings
of the major lipid lowering studies involving statins against
this background. Figure 2A shows the results of three recent
studies plotted against the relationship defined by Pekkanen
et al. (6) in patients who have evidence of coronary artery
disease. Each trial showed significant reductions in both
serum cholesterol and death rate (1–3). However, the slopes
of these relationships are considerably lower than those
defined by Pekkanen et al. (6).
The patients recruited into the LRCPPS usually had
multiple cardiovascular risk factors that were broadly similar
to those present in recruits in the three trials under consid-
eration (Table 1). The curve described by Pekkanen’s data
defines the interplay of multiple coronary risk factors, of
which serum lipid level is but one. Modification of one
factor, such as serum cholesterol, would permit the remain-
ing risk factors to continue their interactions and does not
guarantee that the dependent variable (mortality) would
traverse down the trajectory defined by the original relation-
ships (Figs. 1 and 2) (6). Such an argument could explain
why the statin-treated and placebo groups form a curve with
a flatter slope than that described by Pekkanen (Fig. 2A).
The current debate on lipid lowering therapy focuses on
the degree of the response to treatment. If one were to stay
within the limits imposed by the data, it is clear that it
would not be possible to extrapolate to serum cholesterol
values significantly lower than 170 mg/dl (Fig. 2). Even at
a total cholesterol of 160 mg/dl, a value not achieved in any
of the trials reported thus far, it is evident that these patients
would still retain a risk of approximately six-fold compared
with that anticipated from the LRCPPS data (Fig. 2B). A
similar relationship exists for LDL concentrations (Fig. 3).
The current controversy with respect to treatment for serum
cholesterol (both total and LDL) relates to matters that
could influence the relationship between lipid levels and
death rates within the confidence intervals of the regression
lines (11–13) (Fig. 2B).
In addition to the current preoccupation with statins, the
issue that requires attention is whether one should look
beyond these drugs at other secondary preventive measures.
Over the past few years there has been considerable interest
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in the potential effects of “lifestyle modification” programs
on the prognosis of patients with coronary atherosclerosis
(14–16). These programs integrate conventional outpatient
cardiac care with several other treatment modalities such as
exercise training, dietary management and maneuvers de-
signed to reduce psychosocial stress. Many of these regi-
mens include medications to lower cholesterol concentra-
tions. The American Heart Association and the American
College of Cardiology have recognized the value of some
aspects of such a multidisciplinary approach in their con-
sensus statement on secondary prevention of atherosclerotic
disease (17).
These lifestyle modification studies, however, appear to
have limited results because they are usually small and the
number of patients recruited is insufficient to evaluate effects
Figure 1. Relationship between coronary artery disease mortality
rate and serum cholesterol. The patients with previous evidence of
coronary artery disease (CAD) have a steeper relationship com-
pared with those without. This data is obtained from the Lipid
Research Clinics Program Prevalence Study, in which patients
receive no lipid lowering treatment (6).
Figure 2. (A) The effect of statins on serum cholesterol and
coronary artery disease (CAD) mortality in three clinical trials, 4S
(1), CARE (2) and LIPID (3). In each instance, the open symbols
(, E, h) represent the placebo-treated groups and the closed
symbols (, F, n) represent the drug-treated groups. The
interrupted line is the data from LRCPPS (6), showing the
relationship between serum cholesterol and CAD mortality. (B)
Comparison of the regression lines in the relationship between
statin-treated groups (solid regression line) and the data from
LRCPPS (interrupted line [6]). The confidence intervals for each
line are shown. At serum cholesterol concentrations of approxi-
mately 180 mg/dl, there appears to be a six-fold increase in risk in
the statin-treated group compared with LRCPPS cohort.
Figure 3. (A) The effect of statins on serum LDL and coronary
artery disease (CAD) mortality in three clinical trials, 4S (1),
CARE (2) and LIPID (3). In each instance, the open symbols
(, E, h) represent the placebo-treated groups and the closed
symbols (, F, n) represent the drug-treated groups. The
interrupted line is the data from LRCPPS (6), showing the
relationship between serum cholesterol and CAD mortality. (B)
Comparison of the regression line in the relationship between
statin-treated groups (the solid regression line) and the data from
LRCPPS (interrupted line [6]). The confidence intervals for the
statins are also shown. At serum LDL concentrations of approx-
imately 100 mg/dl there appears to be a 6-fold increase in risk in
the statin-treated group compared to LRCPPS cohort.
Figure 4. Effect of three lifestyle modification trials (SCRIP [13],
HARP [14], AND STARS [15]) and cardiac events. Solid bars
indicate usual care groups and open bars indicate treatment
groups.
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on “hard” primary end-points such as mortality. The statin
trialists avoided this problem by resorting to a multicenter
format that permits much larger numbers of recruits for the
investigations. Because of the relatively simple nature of the
intervention involved, it is possible to maintain an appro-
priate level of quality control in these studies.
Lifestyle modification programs and trials, in contrast,
place great emphasis on the concept that patients exercise
personal responsibility for their health by playing a signifi-
cant role in implementing the intervention. These consid-
erations make it difficult to conduct large, multicenter
clinical trials in which lifestyle modification is the main
intervention. Therefore, investigators have been forced to
rely on small trials and surrogate end-points, such as the
total cardiovascular event rate, to demonstrate therapeutic
efficacy. These provisos notwithstanding, the general con-
sensus that has emerged from these investigations, which
were not limited to lipid lowering strategies (14–16), is that
such programs are effective in reducing the incidence of
major cardiac events (Fig. 4) despite a very modest influence
on the angiographic appearance of patients’ coronary
arteries.
By resorting to less stringent endpoints such as total
cardiovascular events (e.g., hospitalizations for therapeutic
interventions and revascularizations) supported by careful
documentation, it may be possible to undertake clinical
trials in which treatment with a lifestyle modification
program is compared with lipid lowering medication alone.
In both instances, patients could be titrated to a single
serum cholesterol window. If such a design is adopted, it
will be possible for these studies to be completed in those
individual centers that possess infra-structures by which
these services can be implemented. This approach will help
us focus attention away from the limited goal of specific
serum cholesterol levels to a more comprehensive risk
intervention (16–18) in defining therapeutic end points.
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